Lumata Health Secures $23 Million Series B
Summary
Lumata Healths platform addresses these challenges by combining predictive analytics with personalized interventionsrecently demonstrating that up to 800 additional vision-saving eye injections are delivered annually for every 1,000 participating patients. These collaborations have fueled rapid growth and have demonstrated Lumatas effectiveness in improving treatment adherence, enhancing patient satisfaction, and removing barriers to care. By combining advanced technology, predictive analytics, and compassionate care, the company is reshaping how chronic eye diseases are managed and ensuring that more patients retain their vision for years to come.What impressed us most is Lumatas potential to reduce overall healthcare costs while also generating significant value for ophthalmology practices, added Michelle Snyder, Partner at McKesson Ventures. Their proactive, end-to-end solution not only improves patient outcomes, it creates a win-win scenario for everyone involved in the care continuum.As more specialty medicines reach the market, solutions designed to help patients start and stay on their prescribed treatment regimen are increasingly important, said Jason Dinger, Senior Vice President of Strategic Execution at Cencora Ventures. Through a human-led, technology-driven care management platform, Lumata partners with physicians, payers, and pharmaceutical manufacturers to provide tailored interventions that improve clinical outcomes and patient satisfaction while generating additional revenue and reducing downstream healthcare costs.